Antibacterial resistance is a renewed public health plague in modern times, and the COVID-
19 pandemic has rekindled this problem. Changes in antibiotic prescribing behavior …

Abstract Sulbactam/durlobactam (XACDURO®), is a co-packaged antibacterial product that
has been developed by Entasis Therapeutics Inc. for the treatment of infections caused by …

In 2023, the US Food and Drug Administration (FDA) granted approval to a total of 55 new
drugs, comprising 29 new chemical entities (NCEs) and 25 new biological entities (NBEs) …

In 2023, the US Food and Drug Administration has approved 55 novel medications,
consisting of 17 biologics license applications and 38 new molecular entities. Although the …

ABSTRACT Introduction Urinary tract infections (UTIs) are a prevalent health challenge
characterized by the invasion and multiplication of microorganisms in the urinary system …

Carbapenem-resistant Acinetobacter baumannii (CRAB) frequently causes both healthcare-
associated infections and nosocomial outbreaks in burn medicine/plastic surgery and …

Acinetobacter baumannii is a Gram-negative bacillus that can cause severe and difficult-to-
treat healthcare-associated infections. A. baumannii can harbor mobile genetic elements …

We investigated the activity of cefiderocol/β-lactamase inhibitor combinations against clinical
strains with different susceptibility profiles to cefiderocol to explore the potentiality of …

Infectious diseases represent an ever-growing challenge, and antimicrobial resistance
(AMR) poses a significant threat to global health (1–3). Carbapenem-resistant Acinetobacter …

Antimicrobial agents have been a crucial discovery in modern medicine and have
revolutionized the treatment of infectious diseases. However, the rampant overuse and …